Literature DB >> 7620716

Comparative study of endotoxin-induced hypotension in kininogen-deficient rats with that in normal rats.

A Ueno1, H Ishida, S Oh-ishi.   

Abstract

1. The aim of this study was to clarify the role of endogenous bradykinin (BK) in the hypotensive response induced by lipopolysaccharide (LPS) by comparing the degree of hypotension caused by LPS in a strain of specific pathogen-free (SPF) Brown Norway (B/N), kininogen-deficient mutant Katholiek rats with that of B/N normal Kitasato rats. 2. The dose-dependent hypotensive responses caused by intravenous injection of BK (1-100 nmol kg-1) or platelet-activating factor (PAF, 0.003-1 microgram kg-1), were not different in the two strains of rats used. However, there was a strong difference in the hypotensive response induced by LPS in kininogen-deficient and normal rats; in normal rats the hypotensive response was composed of two phases (15 min and 70-80 min after LPS injection), but in kininogen-deficient rats LPS caused a delayed (second phase), but not an acute (first phase) hypotension. 3. We demonstrate that Hoe 140 (1 mg kg-1, i.v.) is a potent, selective, and long-lasting antagonist of the hypotensive effects of BK. Hoe 140 diminished the hypotension caused by LPS in normal rats to the level observed in kininogen-deficient rats, but had no effect on the hypotension caused by LPS in kininogen-deficient rats. 4. TCV309 (0.1 mg kg-1, i.v.) selectively inhibited the hypotension caused by repetitive injection of PAF for up to 180 min. Pretreatment with TCV309 caused a near complete inhibition of the LPS-induced hypotension in kininogen-deficient and normal B/N rats. 5. In the normal rats, dexamethasone (0.5 mg kg-1, i.p.) inhibited the second phase of the hypotension induced by LPS, but not the first phase of the hypotension. 6. A small amount of BK (0.1 nmol kg-1) potentiated the hypotensive action of PAF (0.01 microg kg-1),when they were injected simultaneously.7. In conclusion, we demonstrate that formation of endogenous BK contributes primarily to the acute,but not to the delayed hypotension afforded by endotoxin in the rat. In contrast, formation of endogenous PAF contributes to both the acute and the delayed hypotension afforded by endotoxin in vivo.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620716      PMCID: PMC1510346          DOI: 10.1111/j.1476-5381.1995.tb13340.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  Involvement of nitric oxide pathway in the PAF-induced relaxation of rat thoracic aorta.

Authors:  H Moritoki; T Hisayama; S Takeuchi; H Miyano; W Kondoh
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

2.  GENERAL AND REGIONAL CIRCULATORY EFFECTS OF SYNTHETIC BRADYKININ IN MAN.

Authors:  H A KONTOS; J H MAGEE; W SHAPIRO; J L PATTERSON
Journal:  Circ Res       Date:  1964-04       Impact factor: 17.367

3.  Effect of NG-nitro-L-arginine on shock induced by endotoxin and by platelet activating factor in dogs.

Authors:  K Takekoshi; K Kasai; Y Suzuki; Y Sekiguchi; N Banba; T Nakamura; S Shimoda
Journal:  Eur J Pharmacol       Date:  1993-12-21       Impact factor: 4.432

4.  Effect of the platelet-activating factor antagonist, TCV-309, and the cyclo-oxygenase inhibitor, ibuprofen, on the haemodynamic changes in canine experimental endotoxic shock.

Authors:  S Yamanaka; H Iwao; T Yukimura; S Kim; K Miura
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

5.  Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene.

Authors:  N G Bazan; B S Fletcher; H R Herschman; P K Mukherjee
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

6.  Serum and glucocorticoid regulation of gene transcription and expression of the prostaglandin H synthase-1 and prostaglandin H synthase-2 isozymes.

Authors:  D L DeWitt; E A Meade
Journal:  Arch Biochem Biophys       Date:  1993-10       Impact factor: 4.013

7.  Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide.

Authors:  C Szabó; C C Wu; J A Mitchell; S S Gross; C Thiemermann; J R Vane
Journal:  Circ Res       Date:  1993-12       Impact factor: 17.367

8.  Endothelium-derived kinins account for the immediate response of endothelial cells to bacterial lipopolysaccharide.

Authors:  I Fleming; T Dambacher; R Busse
Journal:  J Cardiovasc Pharmacol       Date:  1992       Impact factor: 3.105

9.  Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies.

Authors:  F J Hock; K Wirth; U Albus; W Linz; H J Gerhards; G Wiemer; S Henke; G Breipohl; W König; J Knolle
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

10.  Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies.

Authors:  K Wirth; F J Hock; U Albus; W Linz; H G Alpermann; H Anagnostopoulos; S Henk; G Breipohl; W König; J Knolle
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

View more
  4 in total

1.  Increased susceptibility to endotoxic shock in transgenic rats with endothelial overexpression of kinin B(1) receptors.

Authors:  Vanessa F Merino; Mihail Todiras; Luciana A Campos; Vera Saul; Elena Popova; Ovidiu C Baltatu; João B Pesquero; Michael Bader
Journal:  J Mol Med (Berl)       Date:  2008-04-19       Impact factor: 4.599

2.  High molecular weight kininogen activates B2 receptor signaling pathway in human vascular endothelial cells.

Authors:  Dhaval Kolte; Noah Osman; Jia Yang; Zia Shariat-Madar
Journal:  J Biol Chem       Date:  2011-05-17       Impact factor: 5.157

Review 3.  The kallikrein-kinin system in health and in diseases of the kidney.

Authors:  Masao Kakoki; Oliver Smithies
Journal:  Kidney Int       Date:  2009-02-04       Impact factor: 10.612

4.  RhoA/Rho-kinase and nitric oxide in vascular reactivity in rats with endotoxaemia.

Authors:  Mei-Hui Liao; Chih-Chin Shih; Cheng-Ming Tsao; Shiu-Jen Chen; Chin-Chen Wu
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.